Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deflazacort PK in Moderate Hepatic Impairment
NCT02286609Phase 1Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Dec 2014
- Primary completion
- Feb 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of deflazacort in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by PTC Therapeutics, Inc. Primary endpoint: Area Under the Plasma Concentration Time Curve at 1 day. Started Dec 2014; status: completed.
02
Drugs
deflazacort
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02286609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286609.